GlaxoSmithKline plc (the 'Company')
Transaction notification
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Sir Andrew Witty
b)
Position/status
Chief Executive Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
GlaxoSmithKline plc
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
Nature of the transaction
Acquisition of Ordinary Shares under the Company's ShareReward Plan.
Price(s) and
volume(s)
Price(s)
Volume(s)
£17.2781
7 (partnership shares)
7 (matching shares)
d)
Aggregated information
Aggregated volume Price
14 Ordinary Shares
e)
Date of the transaction
2016-10-11
f)
Place of the transaction
London Stock Exchange (XLON)
Mr R G Connor
President, Global Manufacturing & Supply
Mr S Dingemans
Chief Financial Officer
Mr N Hirons
SVP, Global Ethics & Compliance
8 (partnership shares)
8 (matching shares)
16 Ordinary Shares
Mr S A Hussain
President, Global Pharmaceuticals
Mr D S Redfern
Chief Strategy Officer
Ms C Thomas
SVP, Human Resources
Mr P C Thomson
SVP, Communications & Government Affairs
Dr P J T Vallance
President, Pharmaceuticals R&D
Ms E Walmsley
CEO Designate
Mrs V A Whyte
Company Secretary